MiMedx Group (NASDAQ:MDXG) Research Coverage Started at Cantor Fitzgerald

Analysts at Cantor Fitzgerald assumed coverage on shares of MiMedx Group (NASDAQ:MDXG) in a research report issued on Tuesday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $11.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 61.29% from the company’s previous close.

Other research analysts have also recently issued research reports about the company. StockNews.com upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Monday, June 3rd. Lake Street Capital started coverage on MiMedx Group in a research report on Thursday, March 7th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of MiMedx Group in a research report on Wednesday, May 1st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Price Performance

MDXG opened at $6.82 on Tuesday. The stock’s 50 day simple moving average is $7.17 and its 200 day simple moving average is $7.62. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.29 and a quick ratio of 2.71. MiMedx Group has a 1 year low of $5.57 and a 1 year high of $9.27. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of 15.50 and a beta of 1.99.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.03. MiMedx Group had a return on equity of 39.42% and a net margin of 18.63%. The firm had revenue of $84.71 million for the quarter, compared to analyst estimates of $79.36 million. As a group, analysts predict that MiMedx Group will post 0.34 earnings per share for the current year.

Institutional Investors Weigh In On MiMedx Group

Several institutional investors have recently bought and sold shares of MDXG. AJOVista LLC acquired a new position in MiMedx Group during the fourth quarter worth $25,000. Headlands Technologies LLC acquired a new stake in shares of MiMedx Group in the first quarter valued at $27,000. Entropy Technologies LP purchased a new position in MiMedx Group in the first quarter valued at $99,000. Loudon Investment Management LLC purchased a new position in MiMedx Group in the fourth quarter valued at $105,000. Finally, KMG Fiduciary Partners LLC purchased a new position in MiMedx Group in the fourth quarter valued at $105,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.